NO-independent activator of soluble guanylyl cyclase (sGC). Activates both isoforms α1β1 and α1β2 of sGC. While the related compound YC-1 (Prod. No. ALX-420-025) also acts as a non-specific phosphodiesterase inhibitor, BAY 41-2272 has no effect on phosphodiesterases. Stimulation of sGC is not blocked by high concentrations of NO scavengers (e.g. PTIO, Prod. No. ALX-430-007) and the combination of BAY 41-2272 with the NO donor DEA NONOate (Prod. No. ALX-430-034) potentiates the activation of sGC. Although BAY 41-2272 alone is not as strong a stimulator of sGC as NO, concentrations as low as 10-100nM stimulate sGC to a level that would be expected to cause biologically important increases in cGMP. ODQ (Prod. No. ALX-270-034), a potent and selective inhibitor of sGC, completely inhibited the effect of BAY 41-2272. The activity of BAY 41-2272 is described in selected literature references.
Product Details
| Alternative Name: | 3-(4-Amino-5-cyclopropylpyrimidine-2-yl)-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine |
| |
| Formula: | C20H17FN6 |
| |
| MW: | 360.4 |
| |
| CAS: | 256376-24-6 |
| |
| Purity: | ≥98% (HPLC) |
| |
| Appearance: | White to off-white needles. |
| |
| Solubility: | Soluble in DMSO, dichloromethane, 100% ethanol or 2-pyrrolidone; practically insoluble in water. |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | +4°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Phosphodiesterase 5 Inhibitor Potentiates Epigallocatechin 3-O-Gallate-Induced Apoptotic Cell Death via Activation of the cGMP Signaling Pathway in Caco-2 Cells: J. Bae, et al.; Curr. Issues Mol. Biol.
44, 6247 (2022),
Abstract;
Soluble guanylate cyclase signalling mediates etoposide resistance in progressing small cell lung cancer: M.W. Schenk, et al.; Nat. Commun.
12, 6652 (2021),
Abstract;
FOXO3 is essential for CD44 expression in pancreatic cancer cells: M. Kumazoe, et al.; Oncogene
36, 2643 (2017),
Abstract;
Cardiovascular and pharmacological implications of haem-deficient NO-unresponsive soluble guanylate cyclase knock-in mice: R. Thoonen, et al.; Nat. Commun.
6, 8482 (2015),
Application(s): Cell Culture,
Abstract;
BAY 41-2272, a soluble guanylate cyclase agonist, activates human mononuclear phagocytes: P.V. Soeiro-Pereira, et al.; Br. J. Pharmacol.
166, 1617 (2012),
Abstract;
Full Text
Soluble guanylyl cyclase contributes to ventilator-induced lung injury in mice: E.P. Schmidt, et al.; Am. J. Physiol. Lung Cell. Mol. Physiol.
295, (2008),
Abstract;
Identification of residues crucially involved in soluble guanylate cyclase activation: C. Rothkegel, et al.; FEBS Lett.
580, 4205 (2006),
Abstract;
Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment: A. Ahluwalia, et al.; PNAS
101, 1386 (2004),
Abstract;
Full Text
BAY 41-2272: a stimulator of soluble guanylyl cyclase induces nitric oxide-dependent penile erection in vivo: E. Bischoff, et al.; Urology
61, 464 (2003),
Abstract;
Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure: G. Boerrigter, et al.; Circulation
107, 686 (2003),
Abstract;
Macrophage endothelial nitric oxide synthase auto-regulates cellular activation and pro-inflammatory protein expression: L. Connelly, et al.; J. Biol. Chem.
278, 26480 (2003),
Abstract;
Full Text
BAY 41-2272 activates two isoforms of nitric oxide-sensitive guanylyl cyclase: M. Koglin, et al.; BBRC
292, 1057 (2002),
Abstract;
NO-independent regulatory site of direct sGC stimulators like YC-1 and BAY 41-2272: E.M. Becker, et al.; BMC Pharmacol.
1, 13 (2001),
Abstract;
Full Text
NO-independent regulatory site on soluble guanylate cyclase: J.P. Stasch, et al.; Nature
410, 212 (2001),
Abstract;
NO-independent stimulators of soluble guanylate cyclase: A. Straub, et al.; Bioorg. Med. Chem. Lett.
11, 781 (2001),
Abstract;
Related Products
